Catalyst
Slingshot members are tracking this event:
PDUFA Date of August 27 for Merck KGaA's (MKGAY) Biologics License Application for Avelumab in Treatment of Metastatic Urothelial Carcinoma With Disease Progression on or After Platinum-Based Chemotherapy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
MKGAY |
|
|
EMD Serono |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 09, 2017
Occurred Source:
https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm557162.htm
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pdufa Date, Biologics License Application, Avelumab, Metastatic Urothelial Carcinoma, Platinum-based Chemotherapy
